| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Javier Avendaño-Godoy, Arnoldo Miranda, Sigrid Mennickent, Carolina Gómez-Gaet. Intramuscularly Administered PLGA Microparticles for Sustained Release of Rivastigmine: In Vitro, In Vivo and Histological Evaluation. Journal of pharmaceutical sciences. 2023-08-26. PMID:37595752. |
rivastigmine is an acetylcholinesterase (ache) and butyrylcholinesterase (bche) inhibitor drug approved by the us food and drug administration (fda) for the treatment of mild to moderate dementia of alzheimer's type. |
2023-08-26 |
2023-09-07 |
rat |
| Lei Wang, Tianyu Sun, Zhenqi Wang, Hui Liu, Weimin Qiu, Xu Tang, Huanchao Guo, Peng Yang, Yao Chen, Haopeng Su. Design, Synthesis, and Proof of Concept of Balanced Dual Inhibitors of Butyrylcholinesterase (BChE) and Histone Deacetylase 6 (HDAC6) for the Treatment of Alzheimer's Disease. ACS chemical neuroscience. 2023-08-10. PMID:37561893. |
design, synthesis, and proof of concept of balanced dual inhibitors of butyrylcholinesterase (bche) and histone deacetylase 6 (hdac6) for the treatment of alzheimer's disease. |
2023-08-10 |
2023-08-16 |
Not clear |
| Lei Wang, Tianyu Sun, Zhenqi Wang, Hui Liu, Weimin Qiu, Xu Tang, Huanchao Guo, Peng Yang, Yao Chen, Haopeng Su. Design, Synthesis, and Proof of Concept of Balanced Dual Inhibitors of Butyrylcholinesterase (BChE) and Histone Deacetylase 6 (HDAC6) for the Treatment of Alzheimer's Disease. ACS chemical neuroscience. 2023-08-10. PMID:37561893. |
concomitant inhibition of butyrylcholinesterase (bche) and histone deacetylase 6 (hdac6) is supposed to be effective in the treatment of alzheimer's disease (ad). |
2023-08-10 |
2023-08-16 |
Not clear |
| Ana Matošević, Dejan M Opsenica, Marta Spasić, Nikola Maraković, Antonio Zandona, Suzana Žunec, Marija Bartolić, Zrinka Kovarik, Anita Bosa. Evaluation of 4-aminoquinoline derivatives with an n-octylamino spacer as potential multi-targeting ligands for the treatment of Alzheimer's disease. Chemico-biological interactions. 2023-07-05. PMID:37406982. |
the most successful therapeutic strategy in the treatment of alzheimer's disease (ad) is directed toward increasing levels of the neurotransmitter acetylcholine (ach) by inhibition of acetylcholinesterase (ache) and butyrylcholinesterase (bche), the enzymes responsible for its hydrolysis. |
2023-07-05 |
2023-08-14 |
human |
| Joanna Grzelczyk, Dominik Szwajgier, Ewa Baranowska-Wójcik, Horacio Pérez-Sánchez, Miguel Carmena-Bargueño, Bożena Sosnowska, Grażyna Budry. Effect of Inhibiting Butyrylcholinesterase Activity Using Fractionated Coffee Extracts Digested In Vitro in Gastrointestinal Tract: Docking Simulation and Calorimetric and Studies. Nutrients. vol 15. issue 10. 2023-05-27. PMID:37242249. |
butyrylcholinesterase (bche) is a major enzyme from the alpha-glycoprotein family that catalyzes the hydrolysis of neurotransmitter acetylcholine (ach), lowering the concentration of ach in the nervous system, which could cause aggravation of alzheimer's disease (ad). |
2023-05-27 |
2023-08-14 |
Not clear |
| Hui Dong, Le Zhao, Tao Wang, Yanan Chen, Wanqing Hao, Ziyi Zhang, Yizhao Hao, Cunliang Zhang, Xiuhua Wei, Yintang Zhang, Yanli Zhou, Maotian X. Dual-Mode Ratiometric Electrochemical and Turn-On Fluorescent Detection of Butyrylcholinesterase Utilizing a Single Probe for the Diagnosis of Alzheimer's Disease. Analytical chemistry. 2023-05-16. PMID:37192372. |
the probe re-bche was synthesized in a single step and demonstrated dual mode response toward butyrylcholinesterase (bche), a promising biomarker of alzheimer's disease (ad). |
2023-05-16 |
2023-08-14 |
Not clear |
| b' Milena Mlaki\\xc4\\x87, Ema \\xc4\\x90ur\\xc4\\x8devi\\xc4\\x87, Ilijana Odak, Danijela Bari\\xc4\\x87, Ines Juri\\xc4\\x8devi\\xc4\\x87, Ivana \\xc5\\xa0agud, Franko Bur\\xc4\\x8dul, Zlata Lasi\\xc4\\x87, \\xc5\\xbdeljko Marini\\xc4\\x87, Irena \\xc5\\xa0kori\\xc4\\x8. Thieno-Thiazolostilbenes, Thienobenzo-Thiazoles, and Naphtho-Oxazoles: Computational Study and Cholinesterase Inhibitory Activity. Molecules (Basel, Switzerland). vol 28. issue 9. 2023-05-14. PMID:37175190.' |
these results are significant as bche has been attracting growing attention due to its positive role in the treatment of alzheimer's disease. |
2023-05-14 |
2023-08-14 |
Not clear |
| Muslum Gok, Cigdem Cicek, Ebru Bodu. Butyrylcholinesterase in lipid metabolism: A new outlook. Journal of neurochemistry. 2023-05-02. PMID:37129444. |
in diseases such as alzheimer, in which elevated bche and impaired lipid levels are observed, the lipolytic activity of bche might be involved. |
2023-05-02 |
2023-08-14 |
Not clear |
| b' Nesrin Korkmaz, Dursun K\\xc4\\xb1sa, \\xc3\\x96zlem Kaplan, Nazan G\\xc3\\xb6k\\xc5\\x9fen Tosun, Aykut \\xc3\\x96zg\\xc3\\xbcr, Rizvan \\xc4\\xb0mamo\\xc4\\x9flu, Ahmet Karada\\xc4\\x9. A Silver Compound with Potential Applications as an Anticancer, Antibacterial, Antifungal, and Anti-Alzheimer. Chemistry & biodiversity. 2023-04-28. PMID:37116090.' |
experimental results show that the compound has inhibitory potential with an ic50 value of 178.10 µm for the bche (butyrylcholinesterase) enzyme, which has a vital role in the progression of alzheimer's disease. |
2023-04-28 |
2023-08-14 |
Not clear |
| Tuan Xu, Shuaizhang Li, Andrew J Li, Jinghua Zhao, Srilatha Sakamuru, Wenwei Huang, Menghang Xia, Ruili Huan. Identification of Potent and Selective Acetylcholinesterase/Butyrylcholinesterase Inhibitors by Virtual Screening. Journal of chemical information and modeling. 2023-04-03. PMID:37011147. |
acetylcholinesterase (ache) and butyrylcholinesterase (bche) play important roles in human neurodegenerative disorders such as alzheimer's disease. |
2023-04-03 |
2023-08-14 |
human |
| Filip Pidany, Jana Kroustkova, Abdullah Al Mamun, Daniela Suchankova, Xavier Brazzolotto, Florian Nachon, Fabien Chantegreil, Rafael Dolezal, Lenka Pulkrabkova, Lubica Muckova, Martina Hrabinova, Vladimir Finger, Martin Kufa, Ondrej Soukup, Daniel Jun, Jaroslav Jenco, Jiri Kunes, Lucie Novakova, Jan Korabecny, Lucie Cahlikov. Highly selective butyrylcholinesterase inhibitors related to Amaryllidaceae alkaloids - Design, synthesis, and biological evaluation. European journal of medicinal chemistry. vol 252. 2023-03-30. PMID:36996715. |
butyrylcholinesterase (bche) is one of the most frequently implicated enzymes in the advanced stage of alzheimer's disease (ad). |
2023-03-30 |
2023-08-14 |
human |
| b' Toma\\xc5\\xbe Trobec, Monika C \\xc5\\xbdu\\xc5\\xbeek, Kristina Sep\\xc4\\x8di\\xc4\\x87, Jerneja Kladnik, Iztok Turel, Robert Frange\\xc5\\xb. Novel Organoruthenium(II) Complex C1 Selectively Inhibits Butyrylcholinesterase without Side Effects on Neuromuscular Transmission. International journal of molecular sciences. vol 24. issue 3. 2023-02-11. PMID:36769002.' |
enzyme butyrylcholinesterase (bche) shows increased activity in some brain regions after progression of alzheimer's disease and is therefore one of the therapeutic targets for symptomatic treatment of this neurodegenerative disorder. |
2023-02-11 |
2023-08-14 |
Not clear |
| Ignazio Schino, Mariangela Cantore, Modesto de Candia, Cosimo D Altomare, Catarina Maria, João Barros, Vasco Cachatra, Patrícia Calado, Karina Shimizu, Adilson A Freitas, Maria C Oliveira, Maria J Ferreira, José N C Lopes, Nicola A Colabufo, Amélia P Raute. Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer's Disease. Pharmaceuticals (Basel, Switzerland). vol 16. issue 1. 2023-01-21. PMID:36678552. |
alzheimer's disease (ad) is characterized by a progressive cholinergic neurotransmission imbalance, with a decrease of acetylcholinesterase (ache) activity followed by a significant increase of butyrylcholinesterase (bche) in the later ad stages. |
2023-01-21 |
2023-08-14 |
Not clear |
| Ashraf K El-Damasy, Jong Eun Park, Hyun Ji Kim, Jinhyuk Lee, Eun-Kyoung Bang, Hoon Kim, Gyochang Keu. Identification of New Pharmaceuticals (Basel, Switzerland). vol 16. issue 1. 2023-01-21. PMID:36678580. |
identification of new monoamine oxidase-b (mao-b), acetylcholinesterase (ache), and butyrylcholinesterase (bche) have been considered target enzymes of depression and neurodegenerative diseases, including alzheimer's disease (ad). |
2023-01-21 |
2023-08-14 |
Not clear |
| Rudra Palash Mukherjee, Geok-Yong Yow, Samuel Sarakbi, Stefano Menegatti, Patrick V Gurgel, Ruben G Carbonell, Benjamin G Boba. Integrated in silico and experimental discovery of trimeric peptide ligands targeting Butyrylcholinesterase. Computational biology and chemistry. vol 102. 2022-12-04. PMID:36463785. |
butyrylcholinesterase (bche) is recognized as a high value biotherapeutic in the treatment of alzheimer's disease and drug addiction. |
2022-12-04 |
2023-08-14 |
Not clear |
| Ana Matošević, Anamarija Knežević, Antonio Zandona, Nikola Maraković, Zrinka Kovarik, Anita Bosa. Design, Synthesis and Biological Evaluation of Biscarbamates as Potential Selective Butyrylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease. Pharmaceuticals (Basel, Switzerland). vol 15. issue 10. 2022-10-27. PMID:36297332. |
as butyrylcholinesterase (bche) plays a role in the progression of symptoms and pathophysiology of alzheimer's disease (ad), selective inhibition of bche over acetylcholinesterase (ache) can represent a promising pathway in treating ad. |
2022-10-27 |
2023-08-14 |
Not clear |
| Ilkay Erdogan Orhan, F Sezer Senol Deniz, Ramin Ekhteiari Salmas, Sule Irmak, Ozden Ozgun Acar, Gurbet Celik Turgut, Alaattin Sen, Ana-Maria Zbancioc, Simon Vlad Luca, Adrianna Skiba, Krystyna Skalicka Wozniak, Gabriela Tataring. Evaluation of anti-Alzheimer activity of synthetic coumarins by combination of in vitro and in silico approaches. Chemistry & biodiversity. 2022-10-25. PMID:36282001. |
series of synthetic coumarin derivatives (1-16) were tested against acetylcholinesterase (ache) and butyrylcholinesterase (bche), two enzymes linked to the pathology of alzheimer's disease (ad). |
2022-10-25 |
2023-08-14 |
human |
| Gokay Albayrak, Serdar Demir, Halil Koyu, Sura Bayka. Anticholinesterase compounds from endemic Prangos uechtritzii. Chemistry & biodiversity. 2022-10-06. PMID:36201258. |
(+)-falcarindiol (ic 50 = 27.88±0.91 μm) and imperatorin (ic 50 = 30.89±1.40 μm) as the most active components could be lead compounds to develop new bche inhibitors with further research against alzheimer's disease. |
2022-10-06 |
2023-08-14 |
Not clear |
| Sani Muhammad Uzairu, Yahaya Tijani, Madu Adamu Gadaka, Babagana Modu, Miriam Watafua, Hadiza Ali Ahmad, Umar Abdullahi Zakariya, Aminu Ibrahim, Aliyu Daja, Hassan Zanna, Abdullahi Balarabe Salla. Kinetics and computational study of butyrylcholinesterase inhibition by methylrosmarinate: relevance to Alzheimer's disease treatment. Heliyon. vol 8. issue 9. 2022-09-23. PMID:36148271. |
butyrylcholinesterase (bche) performs a significant function in alzheimer's disease progression. |
2022-09-23 |
2023-08-14 |
Not clear |
| Muslum Gok, Nimrod Madrer, Tamara Zorbaz, Estelle R Bennett, David Greenberg, David A Bennett, Hermona Sore. Altered levels of variant cholinesterase transcripts contribute to the imbalanced cholinergic signaling in Alzheimer's and Parkinson's disease. Frontiers in molecular neuroscience. vol 15. 2022-09-19. PMID:36117917. |
acetylcholinesterase and butyrylcholinesterase (ache and bche) are involved in modulating cholinergic signaling, but their roles in alzheimer's and parkinson's diseases (ad and pd) remain unclear. |
2022-09-19 |
2023-08-14 |
Not clear |